Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study
Download Full-Text Article

Keywords

endometrial cancer
CA125
lymph node metastases
poor prognostic factors

How to Cite

1.
Yoğurtçuoğlu EE, KOSE G. Investigation of the Role of Preoperative Serum CA 125 Levels in Determining the Necessity of Lymphadenectomy in Cases Diagnosed with Endometrium Cancer: A Retrospective Study. Adv Res Obstet Gynaecol [Internet]. 2023 Dec. 28 [cited 2024 Jun. 16];1(2). Available from: https://arogjournal.org/index.php/arog/article/view/18

Abstract

Objective: The aim of this study is to investigate the relationship between preoperative serum CA 125 levels and clinicopathological parameters in patients operated for endometrial carcinoma (EC) and to reveal the effectiveness of preoperative serum CA 125 levels in determining the necessity of lymphadenectomy.

Materials and Methods: The study included retrospective data of 88 patients who underwent surgery due to EC. The relationship between the patients' preoperative serum tumor marker CA-125 levels and tumor grade, stage, histological type, lymph node positivity was evaluated statistically. The statistical significance of CA-125 levels in determining the need for lymph node dissection was analyzed.

Results: When the preoperative diagnostic methods of the cases were evaluated according to their surgical stage; the mean CA 125 value was 31.21±35.54 (4.4-150.3) IU/ml in early stage (Stage I-II) patients and 349.13±497.34 (19.5-1566) IU/ml in advanced stage (Stage III-IV) patients (p=0.001). Considering the depth of myometrial invasion and preoperative CA 125 values, the mean preoperative CA 125 values were 21.43±20.06 (4.4-44.1) IU/ml in cases with myometrial invasion less than 1/2, while this value was 141.03±329.47 (6.8-1566) IU/ml in cases with more than 1/2 and the difference between the groups was found to be statistically significant (p=0.025).  CA 125 levels of cases with positive lymph nodes were statistically significantly higher than CA 125 levels of cases with negative lymph nodes (p<0.05). While the CA 125 level was 35 IU/ml and above in all cases with positive lymph nodes, the CA 125 level was 35 IU/ml and above in 30.2% of the cases with negative lymph nodes (p<0.05).

Conclusions: The results we obtained in this study support the association of increased preoperative CA 125 levels with lymph node positivity, advanced stage and myometrial involvement above ½ in cases with EC.

https://doi.org/10.62093/e2308
Download Full-Text Article

References

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17. doi:10.1016/0090-8258(83)90111-7

Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. Int J Gynecol Pathol. 2020;39(1):26-35. doi:10.1097/PGP.0000000000000585

Berek JS, Matias-Guiu X, Creutzberg C, et al. FIGO staging of endometrial cancer: 2023. J Gynecol Oncol. 2023;34(5):e85. doi:10.3802/jgo.2023.34.e85

Reijnen C, Visser NC, Kasius JC, et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study. J Gynecol Oncol. 2019;30(5):e70. doi:10.3802/jgo.2019.30.e70

Pinar Cilesiz Goksedef B, Gorgen H, Baran SY, Api M, Cetin A. Preoperative serum CA 125 level as a predictor for metastasis and survival in endometrioid endometrial cancer. J Obstet Gynaecol Can. 2011;33(8):844-850. doi:10.1016/S1701-2163(16)34988-X

Patsner B, Yim GW. Predictive value of preoperative serum CA-125 levels in patients with uterine cancer: The Asian experience 2000 to 2012. Obstet Gynecol Sci. 2013;56(5):281-288. doi:10.5468/ogs.2013.56.5.281

Wu HH, Chou HT, Tseng JY, Chan IS, Chen YJ. The relationship between serum CA-125 level and recurrence in surgical stage I endometrial cancer patients. J Chin Med Assoc. 2023;86(11):1001-1007. doi:10.1097/JCMA.0000000000000985

Price FV, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. CA 125 may not reflect disease status in patients with uterine serous carcinoma. Cancer. 1998;82(9):1720-1725. doi:10.1002/(sici)1097-0142(19980501)82:9<1720::aid-cncr19>3.0.co;2-6

Kurihara T, Mizunuma H, Obara M, Andoh K, Ibuki Y, Nishimura T. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma. Gynecol Oncol. 1998;69(3):192-196. doi:10.1006/gyno.1998.5018

Ignatov A, Ivros S, Bozukova M, Papathemelis T, Ortmann O, Eggemann H. Systematic lymphadenectomy in early stage endometrial cancer. Arch Gynecol Obstet. 2020;302(1):231-239. doi:10.1007/s00404-020-05600-8

Emons G, Kim JW, Weide K, et al. Endometrial Cancer Lymphadenectomy Trial (ECLAT) (pelvic and para-aortic lymphadenectomy in patients with stage I or II endometrial cancer with high risk of recurrence; AGO-OP.6). Int J Gynecol Cancer. 2021;31(7):1075-1079. doi:10.1136/ijgc-2021-002703

Li Y, Hou X, Chen W, Wang S, Ma X. Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study. Sci Rep. 2023;13(1):20270. Published 2023 Nov 20. doi:10.1038/s41598-023-47419-8

Santala M, Talvensaari-Mattila A, Kauppila A. Peritoneal cytology and preoperative serum CA 125 level are important prognostic indicators of overall survival in advanced endometrial cancer. Anticancer Res. 2003;23(3C):3097-3103.

Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984;148(8):1057-1058.

Dotters DJ. Preoperative CA 125 in endometrial cancer: is it useful?. Am J Obstet Gynecol. 2000;182(6):1328-1334. doi:10.1067/mob.2000.106251

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Eser Evrim Yoğurtçuoğlu, Gültekin KOSE

Downloads

Download data is not yet available.